Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
InvestorService: Genmab A/S, Dr. Lisa N. Drakeman Joins Board of Director of Biotechnology Council of New Jersey31 Jan 2005
InvestorService: Genmab, to Present at Biodata 200518 Jan 2005
Genmab, and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial with HuMax-Inflam/MDX-01821 Dec 2004
Genmab, Roche Selects Two Genmab Antibodies as Clinical Candidates17 Dec 2004
Genmab, Genmab’s HuMax-CD20 to Treat CLL Awarded Fast Track Status from FDA16 Dec 2004
Genmab, quarterly statement of shareholdings15 Dec 2004
Genmab, US FDA Accepts Genmab's IND for HuMax-CD20 to Treat Active Rheumatoid Arthritis13 Dec 2004
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
Genmab, financial Calendar
9 Dec 2004
Genmab, HuMax-CD20 Shows Favorable Clinical Responses in NHL5 Dec 2004
Genmab, announces Encouraging Efficacy Data from Humax-EGFr Phase I/II Trial in Head and Neck Cancer1 Dec 2004
Genmab, Grant of Warrants in Genmab A/S1 Dec 2004
InvestorService: Genmab, to Present at ING 4th Annual European Healthcare Conference30 Nov 2004
  • Previous
  • 1
  • More pages
  • 137
  • 138
  • 139
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863